Clinical trials: Epirubicin
HER-2 Positive Breast Cancer
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
The main purpose of this study is to confirm the high pathologic complete response rate after neoadjuvant chemotherapy with FEC followed by weekly paclitaxel and concurrent trastuzumab in Human Epidermal growth factor receptor2…
- Trial name
- NCT01340430
- Testing
- Trastuzumab
- Where
- 6 sites in Italy
- Volunteers
- 43 people
- Sponsor
- Lucia Del Mastro,MD
Early Triple Negative Breast Cancer
A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC).
- Trial name
- NCT06829199
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- 2 sites in United States, Taiwan
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Hepatocellular, Neoplastic Cells, Circulating
Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation
This study is designed to prospectively evaluate whether post-hepatectomy adjuvant transcatheter arterial chemoembolization (TACE) is effective in reducing early recurrence in HCC patients with preoperative CTC ≥2.
- Trial name
- NCT02631499
- Testing
- TACE, Epirubicin, lipiodol
- Where
- 6 sites in China
- Volunteers
- 256 people
- Sponsor
- Fudan University
Sepsis
Epirubicin for the Treatment of Sepsis & Septic Shock
The study will assess the safety of low doses of epirubicin in sepsis patients. Therefore the study will look for side effects in patients treated with low dose epirubicin compared to control patients.
- Trial name
- EPOS-1 (NCT05033808)
- Testing
- Epirubicin
- Where
- 5 sites in Germany
- Volunteers
- 45 people
- Sponsor
- Jena University Hospital
Breast Cancer, HER2-positive Breast Cancer
A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer
In 2020, the incidence of breast cancer surpassed that of lung cancer for the first time, becoming the number one cancer in the world. HER2 is an important prognostic indicator and therapeutic target for breast cancer.
- Trial name
- NCT05474690
- Testing
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab, (Epirubicin + Cyclophosphamide - Docetaxel) + (Trastuzumab + Pertuzumab)
- Where
- China
- Sponsor
- Henan Cancer Hospital
Breast Neoplasm
Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer
Evaluation of efficacy of treatment with epirubicin (5 years follow-up). Evaluation of frequency of dose reduction. Evaluation of frequency of neoadjuvant treatment with E(120mg) / C(600mg).
- Trial name
- NCT01061359
- Testing
- Epirubicin: Observational Study
- Volunteers
- 1,981 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With TACE and HAIC in Unresectable Hepatocellular Carcinoma
Systemic therapy is the primary option for managing advanced hepatocellular carcinoma (HCC). The combination of atezolizumab and bevacizumab (A+B) has emerged as the first-choice treatment for advanced HCC(IM brave 150).
- Trial name
- NCT06199297
- Testing
- Atezolizumab combined with Bevacizumab, Sintilimab combined with Bevacizumab, Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy
- Where
- China
- Volunteers
- 188 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002615
- Testing
- cisplatin, epirubicin hydrochloride, fluorouracil
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Medical Research Council
ORR, PFS
A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma
Given the rarity of nasal and paranasal sinus rhabdomyosarcoma (SNRMS), there is a lack of literature on systemic treatment models for adult SNRMS, let alone prospective clinical studies.
- Conditions
- ORR, PFS, OS
- Trial name
- NCT07449949
- Testing
- VMAT
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Breast Cancer
Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC
Neoadjuvant therapy for HR+/HER2- breast cancer is dominated by anthracycline combined with paclitaxel chemotherapy. Aggressive neoadjuvant chemotherapy can only achieve pCR in about 10% of PATIENTS with HR-positive breast…
- Trial name
- NCT05400993
- Testing
- Chidamide
- Where
- 7 sites in China
- Volunteers
- 59 people
- Sponsor
- Shengjing Hospital
Nasopharyngeal Carcinoma
A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma
Investigate the effect of induction MEPFL chemotherapy followed by concurrent chemoradiotherapy (CCRT) on the disease control and survival in treatment of patients with advanced NPC.
- Trial name
- NCT00201396
- Testing
- CCRT, Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
- Where
- 4 sites in Taiwan
- Volunteers
- 480 people
- Sponsor
- National Health Research Institutes, Taiwan
Neoplasms, Breast
Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer
Evaluate the activity of Trastuzumab, Lapatinib, and a combination of both agents with chemotherapy in the preoperative (neoadjuvant) treatment of early breast cancer.
- Trial name
- CHERLOB (NCT00429299)
- Testing
- lapatinib, trastuzumab, paclitaxel
- Where
- 17 sites in Germany, Italy and 1 more
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Esophageal Neoplasms, Stomach Neoplasms
Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma
The main purpose of this study is to determine the effects of treatment with carboplatin, docetaxel and capecitabine in patients with incurable cancer of the esophagus or stomach.
- Trial name
- SEED (NCT02177552)
- Testing
- Carboplatin, Docetaxel, Capecitabine
- Where
- Denmark
- Volunteers
- 98 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Gastric Adenocarcinoma
ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)
The study addresses two primary questions, according to its factorial design: to compare the efficacy in terms of overall survival (OS) of a peri-operative vs.
- Trial name
- ITACA-S2 (NCT01989858)
- Testing
- peri-operative cht, post-operative CHT, peri-operative cht + post-operative cht-rtx
- Where
- 32 sites in Italy
- Volunteers
- 1,180 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if mitoxantrone is more effective with or without docetaxel.
- Trial name
- NCT00002544
- Testing
- docetaxel, mitoxantrone hydrochloride
- Where
- Germany
- Volunteers
- 300 people
- Sponsor
- Arbeitsgemeinschaft fur Internistische Onkologie
Gastric Cancer
Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong
This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong.
- Trial name
- NCT01679054
- Where
- Hong Kong
- Volunteers
- 58 people
- Sponsor
- Vivian Wing Yan Lee
Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced…
- Conditions
- Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
- Trial name
- NCT06323382
- Testing
- Locoregional therapy, Bevacizumab, Atezolizumab
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Breast Neoplasms, Breast Cancer
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer.
- Trial name
- NCT06797635
- Testing
- Patritumab deruxtecan, Pembrolizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea and 2 more
- Volunteers
- 372 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Breast Cancer
Neoadjuvant Chemotherapy of Primary Breast Cancer With Epirubicin/Docetaxel and Carboplatin/Docetaxel
The purpose of this study is to optimize results in neoadjuvant chemotherapy of local advanced primary breast cancer. Therefore patients become first 3 cycles of Epirubicin/Docetaxel followed by 3x Carboplatin/Docetaxel.
- Trial name
- ETCat01 (NCT00527449)
- Testing
- Epirubicin, Carboplatin, Docetaxel
- Where
- 3 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Klinikum Weissenfels
Diffuse Large B Cell Lymphoma
Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of R-GemOx Versus R-miniCHOP as first-line treatment of elderly patients with Diffuse large B cell lymphoma
- Trial name
- NCT02767674
- Testing
- Rituximab, Gemcitabine, Oxaliplatin
- Where
- 6 sites in China
- Volunteers
- 258 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University